David is a Consultant Paediatrician, Metabolic Physician, Clinical Geneticist and clinician researcher. His area of expertise is the diagnosis and management of children with rare diseases. David is involved in multiple ongoing research projects aimed at novel disease discovery, improved diagnostic testing and treatments for children with inherited genetic disorders. He is director of a national clinic for Ataxia Telangiectasia brashat.org.au and has recently been awarded a $2.5 million NHMRC research grant for a phase 2/3 trial for treatment of this disorder.
We are using the genetic model organism, C. elegans, do investigate the genetic basis of both normal and disordered behaviour. Our current interests are identifying the genes responsible for anxiety and depression as well as the genes for eating disoders and addiction. Using C. elegans as a model organism will also allow us to study gene function as it relates to behaviour.
Molecular mechanisms of phosphine resistance (other research)
Genetic mapping of oxidative stress resistance genes. The fumigant phosphine disrupts oxidative metabolism, resulting in the production of reactive oxygen intermediates. This causes the premature ageing and death of targeted pests. Insect pests of stored grain in Australia now exhibit resistance to phosphine at levels more than 200 times the normal lethal dose.
We have genetically mappedf and identified the genes responsible for phosphine resistance in tall major insect pests of stored grain. We are using a systems biology approach in the model organism C. elegans to understand the molecular basis of phosphine action. Our genetic studies have recently shown that resistance to phosphine is associated with an extension of lifespan
Associate Professor Muttenthaler is a medicinal chemist working at the interface of chemistry and biology with a strong passion for translational research. His research focuses on bioactive peptides and exploring Nature's biodiversity to develop advanced molecular tools, diagnostics, and therapeutics. His background in drug discovery and development, as well as his interdisciplinary training in the fields of chemistry, molecular biology and pharmacology, assist him in characterising these often highly potent and selective compounds to study their interactions with human physiology for medical innovations in pain, cancer, gut disorders and neurological diseases.
